Tropical Journal of Pharmaceutical Research March 2019; 18 (3): 647-667 **ISSN:** 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.

> Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v18i3.29

Original Research Article

External application of Ruyi Jinhuang powder for phlebitis: A systematic review and meta-analysis

Qian Yang¹, Chunyan Yang², Yongqiong Deng³, Qunhua Ma⁴* ¹Nursing School, Southwest Medical University, No. 3, 319 Section of ZhongShan Road, Jiangyang District, ²Department of Dermatology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, No. 16, Chunhui Road, Longma Tan District, ³Department of Dermatology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou 646000, ⁴Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital MICU, Chengdu, Sichuan 610072, China

*For correspondence: Email: qunhua_ma@163.com; Tel/Fax: +86 28-87393999

Sent for review: 21 June 2017

Revised accepted: 17 February 2019

Abstract

Purpose: To systematically review the effectiveness of the external application, Ruyi Jinhuang powder, on phlebitis

Methods: Relevant literature was retrieved from Medline, Embase, China National Knowledge Infrastructure database (CNKI), Cochrane Central Register, Chongqing Vip, Wanfang Data and SinoMed using the search terms "Ruyi Jinhuang San", "Ruyi Jinhuang powder", "Ruyi Jinhuang cream", "Agreeable golden powder", "satisfactory golden powder", "Jinhuang cream", "phlebitis", "prevention and (or) treatment", "randomized controlled trials" and "RCRs". Two researchers independently arranged and analyzed the data.

Results: Significant differences were observed in the total effectiveness rate of Ruyi Jinhuang powder [relative risk (RR) = 1.27, 95% confidence interval (CI) = 1.19 to 1.36, and p < 0.0001). Ruyi Jinhuang powder can reduce the incidence of phlebitis versus conventional therapy in preventing phlebitis (RR = 0.32, 95 % Cl 0.24 to 0.42, and p < 0.0001). Shorten the average healing time [mean difference (MD) =-32.17, 95 % CI= -48.39 to -15.94, and p = 0.0001). Reduced pain relief time for phlebitis (MD = -3.29, 95% CI -5.42 to -1.16, and p = 0.002). However, no statistical difference was observed with regard to the onset time of phlebitis (MD = -0.62, 95 % CI -1.76 to 0.52, and p = 0.29).

Conclusion: Clinicians consider Ruyi Jinhuang powder a viable complementary and alternative medicine for phlebitis following the stronger evidence being offered.

Keywords: Ruyi Jinhuang powder; Prevention and treatment; Phlebitis; Meta-analysis

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Initiative Access (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

In clinical settings, over 80 % of hospitalized inpatients are given intravenous therapy upon admission [1]. A majority of drugs are administered via intravenous injection to maintain highly efficient bioavailability. Approximately, 20 to 70 % of drugs may provoke infusion-induced phlebitis, which is a common and painful complication of peripheral intravenous Such complication significantly cannulation. reduces the drug compliance of patients.

© 2019 The authors. This work is licensed under the Creative Commons Attribution 4.0 International License

Patients with intravenous injection of antibiotics and antineoplastic drugs may develop a high risk of infusion - induced phlebitis. Peripherally inserted central catheters (PICC) - induced Mechanic phlebitis, indwelling needle-induced phlebitis; superficial thrombophlebitis, etc [2]. Phlebitis cause a cascade of unwelcome repercussions-significant swelling, erythema, pain, warmth, thickening and hardening of the injection site and fever [3,4]. Increased prevalence of thrombophlebitis may disrupt the follow-up and negatively impact the physical health of patients. More importantly, the incidence of bacterial phlebitis can compromise subsequent provoke the occurrence of blood infection [5].

Age, gender smoking habit, peripheral vascular diseases, repeated intravenous catheterization, location and duration of catheter indwelling, catheter length and materials, interval of replacement, infusion and filtration devices, type of infused medications that causes lack of sensation (peripheral neuropathy), high-pH drugs and solutions were potentially considered as the risk factors. Other medications and intravenous fluids (vancomycin and benzylpenicillin antibiotics, aminophylline, amiodarone hydrochloride and potassium chloride, aminophylline and amiodarone hydrochloride and 7.4% calcium glubionate, were identified with the strongest phlebitis potential [2-4].

Heparin is associated with the risk of bleeding from the operation site and thrombocytopenia. Corticosteroids are followed by an increased risk of infection through impaired defense system [9]. Local use of anti-inflammatory medications is employed to alleviate the pain of superficial thrombophlebitis, reduce the acute inflammation and discomforts. Nevertheless, whether these therapies can avoid relevant complications remains to be further validated. Thus, it is recommended to use simpler, more economical, and available methods. One of these methods appears to be the use of complementary and alternative medicine.

In China, TCM has been applied to treat human diseases for more than 2000 years. In the history of TCM, physicians have accumulated clinical experience in management of phlebitis [10]. As an integral part of TCM, external application of Ruyi Jinhuang Powder yields lower cost, less adverse events and higher efficacy compared with traditional treatment. Ruyi Jinhuang Powder could also be used on inflammatory external hemorrhoids, acute gouty arthritis anddon't increase adverse reactions [11]. Considerable number of studies demonstrated that Ruyi Jinhuang powder had various pharmacological effects including anti-inflammatory, anti-bacterial, and analgesic effects [12]. Moreover, Ruyi Jinhuang powder could promote granulation, adsorb wound secretion and keep the wound relatively moist [13]. However, the evidence of effectiveness and safety of phlebitis has not been assessed systematically. In addition, substantial numbers of studies could potentially be missed if literature searches are restricted to English-only sources [10].

In previous meta-analyses, the use of Ruyi Jinhuang powder has been applied to treat phlebitis [8,9]. They concentrated on the use of Ruyi Jinhuang powder compared with magnesium sulfate alone. The two meta-analyses were performed in 2010 and 2012, respectively.

METHODS

Data source search

To identify relevant randomized clinical trials (RCTs), two reviewers (Qian Yang and Jian Zhang) performed systematical search from the Medline, Embase, China National Knowledge Infrastructure database (CNKI), Cochrane Central Register, Chongging Vip, Wanfang Data and SinoMed using the search terms "Ruyi Jinhuang San", "Ruyi Jinhuang powder", "Ruyi Jinhuang cream", "Agreeable golden powder", "satisfactory golden powder", "Jinhuang cream", "phlebitis", "prevention and (or) treatment". "randomized controlled trials" and "RCRs." In this meta-analysis, the papers published until September 2016 were researched and included. The reference list of the chosen publications was searched to obtain more relevant articles. We did not limit the language and type of publications. Conference proceedings, abstract-only articles and graduation dissertation were all selected if they met our inclusion criteria (Figure 1).

Study selection

Studies

Random control trials (RCTs) were included. Non-RCTs, Quasi-RCTs, or randomized trials with false randomization method design, mixed intervention, duplicate publication of data, no prescribed duration of treatment, complex TCM formula combined with Ruyi Jinhuang powder, inappropriate clinical outcome assessment and no data for extraction were excluded.




Figure 1: Summary of the literature identification and selection process. CNKI indicates the Chinese National Knowledge Infrastructure database; CQVIP, the Chinese Scientific Journals Full Text database; SinoMed, the Chinese Biomedical Literature Service System; RCT, randomized clinical trials.

Participants

Patients diagnosed with phlebitis based on any set of explicit criteria were included. No restrictive limitations were set on age, gender, nationality, or basic diseases, intravenous injection drugs, phlebitis classification. Retrieval results included 17 chemotherapeutic phlebitis [11-27], 10 PICC-induced phlebitis [28-37], 19 infusion phlebitis [38-56], 7 intravenous indwelling needle-induced phlebitis [57-63] (Table 1 to Table 12). All phlebitis classifications were evaluated based on the Infusion Nursing Standards of Practice proposed by the American Infusion Nurses Society in 2006 [64].

Interventions

The focused experimental groups received

external application of Ruyi Jinhuang Powder. We did not set limitations on dosages, intervals, times and mixtures of it, or types of conventional therapy used. Our comparison of Ruyi Jinhuang powder and conventional therapy included Ruyi Jinhuang powder alone [12,28,30,32,51] or Ruyi Jinhuang powder mixed with vinegar [11,14-17,38,48,52,54,59,60] mixed with honey [1,19-21,23,25,27,29,34,37,39,41,45,46,50,57,58,63 mixed with ethano [18,42,49,61] mixed with tea [22,33,35,43,44,47] mixed with sesameoil [24,31,40,62] mixed with water [26,36] or mixed with glycerin [53,55,56]. The wound sites were dabbed dry with sterile gauze, or the wounds were not debrided but cleaned with normal saline gauze. If they were soiled, then the combined mixtures would be smeared onto the wounds with a sterile gloved finger.

Outcome measurement

To more accurately assess the efficacy of Ruyi jinhuang powder, the primary outcomes as total effectiveness rate (TER) in treating phlebitis, incidence of phlebitis (IP) for preventing phlebitis applied with Ruyi Jinhuang powder were evaluated. The secondary outcomes included average healing time (AHT), pain relief time (PRT) and incidence time of phlebitis (ITP).

Data extraction

Two reviewers (Qian Yang and Jian Zhang) extracted data independently usina а predetermined inclusion criteria. Disagreements were properly solved through mutual discussion or reaching a consensus by the third reviewer (Wen Xin Yang). The data extracted included the first author, year of publication, mean age, sample size, duration of trial period, basic diseases, intravenous infusion drugs, phlebitis classification, topical treatment of control group/experimental group. For studies lacking of sufficient information, the primary authors were contacted to obtain and validate the data. The use of modified JADAD scale evaluation, mainly includes 4 aspects as follow: (1) the generation of random sequence; (2) random hidden; (3) whether the use of blind method; (4) loss of access and withdrawal from the report. The highest score is 7 points, the lowest is divided into 0 points. At present, 1-3 is considered as a low quality, and 4-7 is considered as a high guality (Table 1). Data extraction and guality evaluation process, if there are different views, the use of collective discussion method solved it.

Risk of bias assessment

The risk of bias in each study was assessed by two independent authors (Yong Qiong Deng and Xian Deng) using the Cochrane Risk of Bias tool [65] and disagreements were solved either by consensus or the third reviewer (Wen Xin Yang). Risk of bias and methodological quality of the selected papers are illustrated in Figure 2.

RESULTS

Study selection

The full texts of 237 relevant studies were reviewed from 9277 titles to validate the study eligibility.

Among 237 studies, 184 trials were excluded, including non-RCTs design (n=82), mixed intervention (n=29), duplicate publication of data (n=12), no prescribed duration of treatment

(n=4), complex TCM formula combined with Ruyi Jinhuang powder (n=33), inappropriate clinical outcome assessment (n=18), no data for extraction (n=6). Finally, 53 trials met the inclusion criteria and incorporated into the systematic review. All the selected studies were accomplished in China.

Study characteristics

All included 53 trials were published in Chinese language. In total, 4119 participants were enrolled in these trials (n=2078 in the experimental group and n=2041 in the control group). The sample sizes of these trials ranged from 40 to 240 (Table 1). The dose and frequency of the Ruyi Jinhuang powder differed in each trial. External application of 50% magnem sulphate is the most frequently used in 34 trials. Further therapeutic and preventive measures used in clinical trials.

Risk of bias assessment

The methodological quality of all selected trials was poor (Figure 2). All trials reported the randomization, but merely 12 explicitly described the randomization approach, 6 with random number table [14,17,25,32,36,46], 3 with random case sequence [28,39,65], one the envelope method [30], one based on the admission date [58] and one with convenience sampling method [60], detailed information regarding random sequence generation was absent in the other trials.

Moreover, allocation concealment or blinding of participants and study personnel were described in only one of the trials [36], all of the relevant trials adequately addressed incomplete outcome data, selective reporting could not be judged in all the studies because of the insufficient information provided. We found no other biases in the studies due to low methodological quality. An unclear risk of bias was delivered to all selected studies.

Primary outcomes

Incidence of phlebitis

Fourteen RCTs containing 1418 patients illustrated the results, the experimental group included 714 trials, while the control group included 704 trials, the experimental and control groups received Ruyi jinhuang powder and conventional therapy, respectively. All subjects received fundamental interventions, the 14 independent trials showed heterogeneity in the consistency ($\chi^2 = 20.60$, p = 0.08, f = 37 %).

Table 1: Basic characteristics of the included studies

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Zhang and Li 2016 [11]	80(40/40)	Sex:E:25/15 C:23/17 Age:E:m=58 C:M=53	2012.12- 2013.12	Chemotherapy-induced phlebitis Chemotherapeutic drugs: vinorelbine, paclitaxel, fluorouracil, leurocristine, cisplatin, carboplatin, Cyclophosphamide, pharmorubicin)	Give 0.9% normal saline water or 5% glucose 10-20 mL fast rapid intravenous injection, and to dilute the residual chemical therapy drug content on blood vessel walls, and from the reducing of veins	External application of Ruyijinghuang Powder combined with winegar at 1 mm thickness for 12 hours, once a day for 5 days	IP	3
Yang et al 2013 [12]	60(30/30)	Sex:All women Age:E:28-53 M=45 C:27-55 M=46	2011.2-2012.9	Chemotherapy-induced phlebitis Chemotherapeutic drugs: Fluorouracil department of gynecology	external application of 50%magnem sulphate (MgSO ₄) 8-10 ml ,20 min a time	external application of Ruyijinghuang Powder at 2mm thickness, once a day	IP	3
Jiang 2010 [13]	50(25/25)	Sex:All women Age:35-60 M=45	2008.1- 2009.2	Chemotherapy-induced phlebitis Diseased:radical mastectomy Chemotherapeutic drugs Cyclophosphamide, pharmorubicin, 5 fluorouracil	Conventional care not take preventive measures	External application of Ruyijinhuang powder 15g mixed with honey at 2 mm thickness for 8 hours, twice a day	IP	3
Li 2012 [14]	(85/83)	Sex:55/45 Age:30-68	2010.3- 2011.3	Chemotherapy-induced phlebitis non- small cell lung cancer, breast cancer, acute nonlymphocytic leukemia Blistering chemotherapy drugs (vinorelbine, Doxorubicin)	Dexamethasone sodium5 mg, sodium aescinate5 mg, add into 10ml sodium chloride solution, intravenous push for several times	external application of Ruyijinghuang Powder combined with winegar at 5mm thickniss for 24 hours	IP	4
Cheng 2012 [15]	120(60/60)	Sex:68/52 Age:28-76	2010.3-2011.3	Chemotherapy-induced phlebitis Diseases: esophageal carcinoma29, gastric cancer47, colon cancer20, pancreatic cancer7, breast cancer1, endometrial carcinoma3, gallbladder 2	infrared radiation for 0.5 hour once a day	external application of Ruyijinghuang Powder combined with winegar once a day	IP	3
Zhou 2013 [16]	48(24/24)	Sex:35/13 Age:38-75 M=64	2011.3- 2012.12	Chemotherapy-induced phlebitis Disease: Gastric cancer17, colorectal cancer 17, breast cancer13, colon cancer Phlebitis :E: grade I 20, grade II 16, grade III 12	external application of 50%magnem sulphate (MgSO ₄) for 30 minutes, 7 days as a course	Ruyijinhuang powdermixed with vinegar once a day, 7 days as a course	TER	3

Table 1: Basic characteristics of the included studies (continued)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Sun and Li 2015 [17]	50(25/25)	Sex: E: 17/8 C:11/14 Age:E:38-75 (57.3±7.4) C:36- 77(57.8±7.6)	2010.2- 2014.10	Chemotherapy-induced phlebitis E:grade I3, grade II 5, grade III 17 C:grade I 2, grade II 4, grade III 19	cold compress of 50%magnem sulphate (MgSO ₄) for 24 hours, along with hot compress for the next 24 hours	external application of Ruyijinhuang powder 9g mixed with distilled vinegar 10 ml and honey 2 ml at 6 hourly intervals	TER	4
Yu et al 2010 [18]				Chemotherapeutic phlebitis-induced by indwelling needle Diseases: gastric cancer18, breast cancer12, endometrial cancer19, lung cancer9, liver cancer5, colon cancer12, pancreatic carcinoma8, lymphoma5Chemotherapeutic drugs:Vinorelbine, pharmorubicin	External application of Hot towel (Temperature of 40 ~ 50 °C)	Wet compress of ruyi jinhuang powder 50 g dissolved in ethanol 50 ml for 2 h, once a day, 7 days as a course	TER	3
You et al 2010 [19]	60(30/30)	5/25 5/25 25-78	2007.9-2009.6	chemotherapy-induced phlebitis (Cyclophosphamide, cisplatin, PTX(paclitaxel) Thiotepa, ADM doxorubicin)	external application of hirudoid cream 2-3times a day	ruyiinhuang powder mixed with honey at 0.5 mm thickness 2-3cm for 12h,twice a day	TER	3
Wu 2008 [20]	86(43/43)	Sex:56/30 Age:31-76 M=51.3	2006.5-2007.10	Chemotherapy-induced phlebitis grade I25, grade II 41, grade III 20 gastric cancer20, breast cancer15, endometrial carcinoma11, lung cancer9, liver cancer12, colon cancer14, lymphoma4	infrared radiation for 15 min, twice a day,7 days as a course	Wet compress of Ruyijinhuang powdermixed with honey for 24 h, once a day, 7 days as a course	TER	3
Liu 2011 [21]	40(20/20)	Sex:16/24 Age:33-75 M= 55.2±8.3	2008.2-2009.10	Chemotherapy-induced phlebitis Leukemia, multiple myeloma, lymphoma E:grade I6, grade II 11, grade III 3 C:grade I6, grade II 12, grade III 2	external application of 50% magnem sulphate (MgSO ₄) for 12h : Cooperate with external application of wet Towel (50 °C) 30 minutes a time, 2 times/d	external application of Ruyijinhuang powder 5g mixed with honey at 1 mm thickness for 10 minutes, twice a day	TER	3
Meng 2011 [22]	60(30/30)	Sex:7/53 Age:31-78 M=50.85	2010.1-2011.7	Chemotherapy-induced phlebitis chemotherapy drugs: Paclitaxel cyclophosphamide, Fluorouracil, Epirubicin. Phlebitis: grade I 37, grade II 19, grade III4	external application of 50%magnem sulphate $(MgSO_4)$,2-3 times a day	Ruyijinhuang powdermixed with dense tea at 3mm thickness.	TER	3

Table 1: Basic characteristics of the included studies (continued)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Liang 2012 [23]	68(34/34)	Sex:38/30 Age:28-73 M=51.2	2009.1- 2011.6	Chemotherapeutic phlebitis disease: nasopharyngeal carcinoma (NPC)15, lung cancer24, esophageal cancer 14, malignant lymphoma5, rectal cancer3, breast cancer7,Phlebitis:E:grade I 15, grade II 12, gradeIII7 C:grade I 18, grade II 10, gradeIII6	hot-wet compression of 50% magnesium sulphuricum at 4 hours intervals ,3 days as a course	external application of RuyiJinhuang Powder mixed with honey at 3mm thickness at 12 hours intervals, 3 days as a course	TER	3
Kang et al 2013 [24]	59(30/29)	Sex:41/18 Age:32-69 M=52	2012.1- 2012.10	Chemotherapy non exosmosis phlebitis Desease:Small cell lung cancer20, adenocarcinoma15, squamous carcinoma14, esophageal7, breast cancer3;Chemotherapeutic drugs: Carboplatin,cisplatin, docetaxel, paclitaxel, fluorouracil, etoposide, gemcitabine, doxorubicin	external application of 50%magnesium sulphate (MgSO ₄) 2 times a day	external application of Ruyijinhuang powder mixed with sesame oil 50% magnesium sulfate once a day。	TER	3
Wang et al 2014 [25]	(60/60)	Sex: 62/58 Age: 36-72	2013.10- 2014.4	Chemotherapy-induced phlebitis Diseases:lung cancer 36, gastric cancer 27, liver cancer 20, breast cancer20, colon cancer17	External application of 50%magnem sulphate (MgSO ₄)	external application of Ruyijinhuang powder mixed with honey at 3mm thickness for 72 hours	IP	4
He 2012 [26]		Sex:E:28/12 C:25/15 Age:E:31- 70,M=50.5 C:22- 75,M=48.6	2010.8- 2011.8	Chemotherapy-induced phlebitis Diseases:E:16 lung cancer, gastric cancer 8, 6 breast cancer, esophageal cancer3, colon cancer 7 C:lung cancer 15, 10 gastric cancer, colorectal cancer 8, esophageal cancer 2, breast cance5 Chemotherapeutic drugs:Gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, doxorubicin	Conventional care not take preventive measures	external application of Ruyijinghuang Powder mixed with distilled water, at 2mm thickness	IP	3
Wei 2009 [27]	86(43/43)	Age:17- 82	2006.9- 2008.7	Chemotherapy-induced phlebitis Vinorelbine, pirarubicin, mitoxantrone, Docetaxe	external application of 50%magnem sulphate (MgSO ₄) for 4 hours	external application of Ruyijinhuang powder mixed with honey at 0.5-1mm thickness for 4 hours, 2~ 3d	IP	3

Table 1: Basic characteristics of the included studies (continued)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Xiong and Yang 2013 [29]	74(38/36)	Sex:36/38 Age:18-65 M=42.0	2011.1-2.13.1	PICC-induced Mechanic Phlebitis breast cancer25, liver cancer15, cervical cancer13, lung cancer21	external application of 50%magnem sulphate (MgSO ₄)	external application of Ruyijinhuang powder mixed with honey at 1mm thickness at 24 hourly intervals	TER AHT	4
Gao and Li 2012 [30]	108(54/54)	Sex:67/41 Age:4-81 M=40.6±7.1	2010.2-2011.1	PICC-induced Mechanic Phlebitis(Cisplatin (DDP) and fluorouracil) brain cancer22,nasopharyngeal carcinoma68, laryngeal cancer13, carcinoma of the parotid gland5	Infrared radiation twice a day for 3 days	external application of Ruyijinghuang Powder at 0.5-1.0 cm thickniss,twice a day for 3 days	IP	4
Liu Y and Yang LY 2009 [31]	74(40/34)	Sex:E:28/12 C:22/12 Age:M=35.2 C:33.8	2007.1-2009.3	PICC-induced Mechanic Phlebitis	external application of wet Towel (45-50 °C)for 30 min ,twice a day,7 days as a course	external application of Ruyijinghuang Powder combined with sesame oil once a day, 7 days as a course	IP	3
Duan PP et al.,2008 [32]	240(120/120)	Sex:E:78/42 C:78/42 E:21-89(58. 45±13.38) C:16-96(59. 58±14. 85)	2005.10-2007.6	PICC-induced Mechanic Phlebitis	Conventional care not take preventive measures	external application of Ruyijinghuang Powder once a day for 3 days	IP ITP	4
Zhu et al 2008 [33]	42(21/21)	Sex:38/4 Age:E:2.6±3.8 5 C:82.5±3.7		Phebitis afterPICC catheteterization in eldedypatients Non-Hodgkin lymphoma28, myelodysplastic syndrome9, acute myelogenous leukemia5 Phebitis :E:grade I5, grade II 14, grade III 2 C:grade I7, grade II 12, grade III 2	Ultrashort wave therapy for 20 minutes, twice a day	Rnyijinhuang powder 12 g mixed with Warm tea at 1mm thickness for40 minutes ,2-3times a day	TER	34

Table 1: Basic characteristics of the included studies (contd)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C (months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Li et al 2007 [34]	62(32/30)	Sex:26/36 Age:13-73 M=35+2.5	2004.6- 2007.2	PICC-induced Mechanic Phlebitis department of hemopathology and oncology	external application of 50%magnem sulphate (MgSO ₄) for 12h; Cooperate with infrared therapeutic apparatus irradiation, 30 rain each time, 2 times a day.	external application of Ruyijinhuang powder mixed with honey for 24 hours	TER ATP	3
Zhu et al 2009 [35]	70(36/340)	Age:20- 70M= 42.13	2005.1- 2008.1	PICC-induced Mechanic Phlebitis	external application of hirudoid cream ,4 times a day, for 2-4 days。	external application of Rnyijinhuang powder 5 g mixed with The filtered tea water 10ml 4 times a day, for 2-4 days	TER	3
Peng and Wang 2015 [36]		28/4,M=73	2008.1- 2010.3	PICC-induced phlebitis Disease:colorectal cancer Chemotherapy drugs:Oxaliplatin, calcium, folinate fluorouracil	wet compression of 50%magnem sulphate (MgSO ₄) infrared radiation for 20 minutes qn	external application of Ruyijinhuang powder 12g mixed with warm water 39-40°C for 30minutes,3 times a day, 5 days as a course	TER	5
Shi et al 2011 [37]	73(37/36)	Age:20-75 M=42± 2.5	2007.10- 2010.10	PICC-induced Intermittent phlebitis	external application of Hirudoid ointment combined with infrared therapy for 30 minutes, twice a day,	external application of Ruyijinhuang powder mixed with honey at 24 hours intervels	TER ATP	3
Yao 2015 [38]	86(43/43)	Sex:All woman Age:30-62 M=41.6±10. 1	2013.6- 2014.10	Infusion phlebitis	external application of 50%magnesium sulphate (MgSO ₄); once a day, 4 days as a period of treatment.	Ruyijinhuang powder mixed with vinegar once a day, 4 days as a period of treatment.	TER	3
Yu H2016[40]	80(40/40)	Sex:E:3I/9 C:32/8 Age:E:8- 80M=44 C:6- 78M=47)	2013.1- 2014.1	Infusion phlebitis(fat emulsion, Intravenous indwelling needle20, Mannitol20,other drugs26)	External application of 50%magnesium sulphate(MgSO ₄)3times a day,5 days as a course	Ruyijinhuang powder mixed with sesame oil twice a day, 5 days as a course	TER	3

Table 7: Basic characteristics of the included studies (contd)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Huang and Liu 2004[39]	62(31/31)	Sex:25/37 Age:27-80	1995.1-2002.3	Infusion phlebitis(Potassium chloride, nutrient solution and chemotherapy drugs) Disease:E:subtotal gastrectomy7, liver cancer2, colon cancer 3, acute pancreatitis4, Choledocholithotomy7 8 postoperative lung cancer 8/ C:subtotal gastrectomy 5 Choledocholithotomy 8, postoperative lung cancer 6, breast cancer 4, kidney carcinoma liver cance2, acute intestinal obstruction5 E:grade 16, grade II 24, grade III 1 C:grade 18, grade II 22, grade III 1	external application of 50%magnem sulphate (MgSO₄)	external application of Ruyijinhuang powder mixed with honey at 3mm thickness for aborve 12 hours once a day	TER	4
Wu 2015 [41]	62(31/31)	Sex:48/ 14 Age: 42-89	2014.1-2015.7	Infusion phlebitis E:grade I16, grade II 14, grade III 1 C:grade I8, grade II 22, grade III 1	hot-wet compression of 50%magnem sulphate (MgSO₄)	external application of Ruyijinhuang powder 12g mixed with honey at 1mm thickness for 3-5 days	TER	3

Table 1: Basic characteristics of the included studies (continued)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADA D
Yan and Xu 2015 [42]	52(26/26)	Sex:24/28 Age:26-74 M=58.77 ±13. 18	2012.9- 2013.6	Infusion phlebitis transfusion drugs:Potassium chloride, dopamine, fat emulsion ,levofloxacin Phlebitis:E:grade I 4, grade II 20, grade II 2 C:grade I 6, grade II 18, grade III 2	external application of 50%magnem sulphate (MgSO ₄) for 120minutes,twice a day	external application of Ruyijinhuang powder mixed with35%-40% ethanol at 1mm thickness, for 120minutes,twice a day	TER ATP	3
Liu <i>et al</i> 2014 [43]	56(28/28)	Sex:30/26	2011.10- 2013.10	Infusion phlebitis Phlebitis:grade I 36, grade II 18, grade III 2	external application of 50%magnesium sulphate (MgSO ₄) 2-3times a day,5 days as a course	external application of RuyiJinhuang Powder 15g mixed with Green tea water at 2mm thickness for 24hours, at 8 hours intervals, 5 days as a course	TER	3
Zhang et al 2007 [44]	60(30/30)	Sex:36/24 Age:41-78	2003.8- 2006.8	Infusion phlebitis (Potassium chloride injection, amiodarone, nitric acid glycerin, dopamine and levofloxacin)	external application of 50%magnem sulphate (MgSO ₄), Cooperate with external application of wet Towel (50 °C)for 30 min ,twice a day	Rnyijinhuang powder 5 g mixed with dense tea,at 3 mm thickness for 10min,twice a day	TER	3
Liu et 2012 [45]	100(50/50)	Sex:78/22 Age:35-71 M=51	2010.1- 2012.1	Amiodarone induced phlebitis E:grade I34, grade II 15, grade III 3 C:grade I33, grade II 10, grade III 5	external application of 50%magnesium sulphate (MgSO ₄)	external application of Ruyijinhuang powder 5g mixed with honey	TER	3
Zhang and Zhao 2015 [46]	60(30/30)	Sex:E:16/14 C:14/16 Age:E:62±5.4 C:61±4.8	2014.7- 2017.12	Amiodarone-induced phelebitis Phlebitis:E:grade I 8, grade II 16, grade III 6 C:grade I 7, grade II 17, grade III 6	external application of 50%magnem sulphate (MgSO ₄) at 6 hours intervel	external application of Ruyijinhuang powder mixed with honey at 3mm thickness, at 6 hours intervel	TER ATP PRT	4
Dai 2013 [47]	44(23/21)	Sex:29 /15 Age:40-83 M=66.25±12.0 2	2011.1- 2012.12	amiodarone-induced phlebitis	Conventional care not take preventive measures	Rnyijinhuang powder 5 g mixed with dense tea at 2mm thickness for 8 -10hours,twice a day	IP	3

Table 9: Basic characteristics of the included studies (contd)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Huo and Chang 2013 [48]	60(30/30)	Sex:33/27 Age:35-78M= 54.23±5.52	2008.10- 2012.10	amiodarone-induced phlebitis	external application of 50%magnesium sulphate (MgSO ₄); 30 minutes each time, 3 times a day, 3 days as a period of treatment.	Ruyi j inhuang Powder 15g mixed with vinegar at 0.5 mm thickness	TER	3
Chen et al 2013 [49]	60(30/30)	Sex:E:21/9 C:21/9 Age:E:36- 78,M=67 C: 32-85,M=70	2011.1- 2012.2	amiodarone-induced phlebitis in CCU department Phlebitis:E:grade I 17, grade II 9,grade II4 C:grade I 13, grade II 11, gradeII6	external application of 50% magnem sulphate (MgSO ₄) : twice a day	external application of Ruyijinhuang powder mixed with 75%ethanol at 3mm thickness for 8-12 hours twice a day	TER ATP PRT	3
Fu 2016 [50]	146(82/64)	Sex: E:34/30 C:43/39	2015.1- 2015.12	sodium β-seven-induced phlebitis E:grade I 36, grade II 27, grade II 19 C:grade I 28, grade II 22, grade III 14	wet compress of 50% magnesium sulphuricum for 1 hours, 3times a day, 5 days as a course	external application of RuyiJinhuang Powder tuned into a paste with honey at 2mm thickness for 22 hours, once a day, 5 days as a course	TER	3
Li et al 2013 [51]	80(40/40)	Sex:38/42 Age:M=52.3	2011.3- 2012.9	fat emulsion-induced phlebitis diseases:severe acute pancreatitis62, tumor14, malnutrition4	external application of 50%magnesium sulphate (MgSO ₄) 50g dissolved in 100mL warm water (40 -45°C) cooperate with microwave physiotherapy15-30 minutes,2-3 times a day 10-20 min each time	hydropathic compress of Ruyi Jinhuang powder 7 days for a course of treatment	TER ATP PRT	3
Yang 2012 [52]	75(37/38)	Sex:52/23 Age: 35-78	2010.1- 2012.5	mannitol-induced phlebitis Phlebitis:E:grade I 27, grade II 10, gradeIII 0 C:grade I 30, grade II 8, gradeIII 0	external application of 25%magnem sulphate (MgSO ₄)	external application of Ruyijinhuang powder 2- 3g mixed with vinegar at 2mm thickness	TER	3
Yang 2012 [52]	75(37/38)	Sex:52/23 Age: 35-78	2010.1- 2012.5	mannitol-induced phlebitis Phlebitis:E:grade I 27, grade II 10, gradeIII0 C:grade I 30, grade II 8, gradeIII0	external application of 25%magnem sulphate (MgSO ₄)	external application of Ruyijinhuang powder 2- 3g mixed with vinegar at 2mm thickness	TER	3

Table 1: Basic characteristics of the included studies (continued)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Tang G and Meng JH 2012[53]	60(30/30)	Sex:36/24 Age:37-72 M=68±9	2007.3- 2010.9	Gadopentetate dimeglumine - induced phlebitis grade I40, grade II 18, grade III 2	external application of 50%magnem sulphate (MgSO₄) twice a day	external application of Ruyijinghuang Powder combined with glycerinum, twice a day	TER	3
Li et al 2010 [55]	100(50/50)	E:75-82M=78.5± 3.2) C:75-84M= (79.9± 2.9)	2008.10- 2009.6	Alprostadil-induced superficial phlebitis	external application of Dermlin dressing, once a day	external application of Ruyijinghuang Powder 12g combined with glycerinum 20ml for 30 minutes, 2-3 times a day 3 days as a course	TER	3
Mei 2010 [56]	100(50/50)	Sex:48/52 Age:63-84	2009.3- 2009.12	superficial phlebitis E:grade I, grade II 17, gradeⅢ6 C:gradel 30, grade II 17例, grade Ⅲ3	external application of Dermlin dressing, once a day	external application of Ruyijinghuang Powder 12g combined with glycerinum 20 mL, at 0.3 cm thickniss, 2-3times a day, 7 days as a course	TER	4
Zhang and Wang 2013 [57]	50(25/25)	Sex: 28/22 Age:50-90 M= 70	2012.8- 2012.12	indwelling needle- induced phlebitis	Conventional care not take preventive measures	external application of Ruyijinhuang powder mixed with honey for 12 hours, twice a day	IP	3
Zhou et al 2012 [58]	128(64/64)	Age:E:28- 70(52.22+12.98) C:26- 72(52.47+13.32)	2009.1- 2010.10	indwelling needle- induced phlebitis desease:cervical carcinom Chemotherapeutic drugs: Fluorouracil	Conventional care not take preventive measures	external application of RuyiJinhuang Powder 15g mixed with honey for 24hours, 5 days as a course	IP ITP	4
Yu et al 2010 [59]		Sex:30/18 Age: 25-83	2008.1- 2009.12	indwelling needle-induced phlebitis phlebitis:grade I 35, grade II 13	external application of 50%magnem sulphate (MgSO ₄) : Cooperate with external application of hot-water bag ,at 4 hours intervels,5 day as a course	external application of Ruyijinhuang powder mixed with vinegar at 0.2- 0.4cm thickness, once a day ,5 day as a course	TER	3
Xin 2012 [60]	60(30/30)	Sex:32/28 Age:26-82 M=54±12.5	2010.1- 2011.1	indwelling needle- induced phlebitis cardiothoracic surgery department	external application of 50%magnem sulphate (MgSO ₄) , Cooperate with external application of hot-water bag (50 °C) ,4 times a day,7 days as a course	Ruyijinhuang powder 9g mixed with distilled vinegar 20 ml at 12 hourly intervals, 7 days as a course	TER	4

Trop J Pharm Res, March 2019; 18(3):659

Table 1: Basic characteristics of the included studies (continued)

Study	Sample size E/C	Sex or Age E/C (Mean ± SD) years	Duration E/C(months)	Phlebitis E/C basic Diseases E/C Drugs E/C Phlebitis classification E/C	Topical treatment of control group	External application of experimental group	Main outcomes	JADAD
Xu et al 2011 [61]	120(60/60)	40/20(2-84M= 43) 38/22 (4- 80M=42)	2008.6- 2010.6	indwelling needle- induced phlebitis E:Swelling type 37, vascular sclerosis type 21, necrosis Type 2 C:Swelling type 36, vascular sclerosis type 22, necrosis type2	0.5% povidone iodine solution cotton swab sterile needle, anisodamine10mg plus NS soaked 10 ml sterile gauze to cover, cover with plastic wrap. 30 minutes each time, 2 times a day, 5 days as a period of treatment.	Ruyi jinhuang Powder mixedwith ethyl alcohol (applied the Ruyi jinhuang Powder which had been put on the gauze evenly to the damaged skin according to its Size)as well as TDP based on sys temic, twice per day , 30 minutes each time, 5 days as a course.	TER	3
Song et al 2014 [62]	32(16/16)	Sex:E:20/17 C:21/15 Age:E:60-72.5 C:60.5-71.9	2012.5- 2014.1	indwelling needle- induced phlebitis	external application of 50%magnesium sulphate (MgSO ₄) 50g dissolved in 100mL warm water (40 -45°C) 3 times a day 10-20 min each time,4-6 days as a course	Ruyijinhuang powder mixed with sesame oil twice a day, 4-6 days as a course	TER	3
Liu and Zhou 2012 [63]	46(23/23)	Sex:30/16 Age:22-85	2010.1- 2011.8	indwelling needle- induced phlebitis (breast cancer 6, lung cancer 18, colorectal cancer 10/ cervical cancer 8, brain tumor 2, non-Hodgkin's lymphoma 2)	external application of 50%magnem sulphate (MgSO ₄) for 2h,3times a day,3days as a course	Ruyijinhuang powdermixed with honey for 12h, once a day, 3days as a course	TER	3

Thus, randomized-effect model should be used for statistical analysis. The combined effects showed that there was some beneficial evidence regarding the effect on reducing incidence of phlebitis after external application of Ruyi jinhuang powder versus conventional therapy (RR = 0.32, 95 % Cl = 0.24 and 0.42, and p <0.0001) (Figure 3).



Figure 3: Meta-analysis of the incidence rate of phlebitis Ruyi jinghuang powder versus conventional therapy based on the same intervention strategies in preventing phlebitis. Cl indicates confidence interval

Total effectiveness rate of Ruyi Jinhuang powder versus conventional therapy in treating phlebitis

39 RCTs contained 2701 patients illustrated the results. The experimental group (1364 trials) and control groups (1337 trials) received Ruyi Jinhuang powder and conventional therapy, respectively. The 39 trials yielded significant heterogeneity (χ^2 =171.17, *P*<0.0001, *P*=78%). Thus, random-effect model should be used for statistical analysis.

The aggregated results indicated that comparison revealed significant differences in total effectiveness rate of Ruyi Jinhuang powder versus conventional therapy groups (RR = 1.27, 95% CI = 1.19, 1.36, and *P*<0.0001).

Significant differences were also found between subgroups of chemotherapy-induced phlebitis (RR = 1.19, 95% Cl = 1.10, 1.27, and p < 0.0001). PICC-induced phlebitis (RR = 1.65, 95% Cl = 1.39, 1.96, and p < 0.00001). infusion phlebitis (RR = 1.21, 95% Cl = 1.10, 1.33, and p = 0.0001) and indwelling needle-induced phlebitis (RR = 1.28, 95% Cl = 1.08, 1.52, and p = 0.007; Figure 4 to Figure 6).

Secondary outcomes

Average healing time

Seven RCTs consisting of 461 patients illustrated the results. The experimental group included 233 trials, and the control groups included 228 trials. The 7 trials shown significant heterogeneity (χ^2 =303.59, p < 0.00001, $\hat{f} = 98$ %) compared to conventional therapy. External application of Ruyi jinhuang powder exerted a superior effect on the average healing time using the random-effect model (MD = -32.17, 95 % CI = [-48.39, -15.94], and *P*=0.0001) (Figure 7).

	Experim	ental	Contr	ol		Risk Ratio	Risk Rutio
Study of Subgroup	Events	Total	Events	Tetal	Weight	M-H. Random, 95% Cl	M-H, Random, 95% CI
Cheng HJ2012	10	60	33	60	10.4%	0.30 [0.16, 0.66]	
Dui WD 2013	4	23	17	21	6.4%	0.21 [0.09, 0.64]	
Duan PP et al., 2008	4	120	30	120	5.5%	0.13 [0.05, 0.37]	
Gao VQ and Li L2012	4	- 54	13	54	5.2%	0.31 [0.11, 0.88]	
He WG2012	12	40	25	40	11.9%	0.48 [0.28, 0.82]	
Jiang YJ2010	1	30	15	30	8.4%	0.47 [0.22, 0.98]	
Li J2012	5	85	38	83	6,7%	0.14 [0.06, 0.33]	
Liu Y and Yang LY 2009	2	40	8	34	3.0%	0.21 (0.05, 0.93)	
Wang Y et al., 2014	4	60	13	60	5.1%	0.31 [0.11, 0.99]	
Wel HA 2009	3	43	13	43	1.4%	0.23 [0.07, 0.76]	
Yang X2013	14	30	24	30	14.2%	0.58 (0.38, 0.89)	
Zhang L and Li L2016	5	40	12	40	6.1%	0.42 [0.16, 1.07]	
Zhang 8Z and Wang Y2013	2	25	9	25	3.2%	0.22[0.05, 0.93]	
Zhou FF et al.,2012	9	64	29	64	9.5%	0.32 [0.17, 0.63]	
Total (95% CI)		714		704	100.0%	0.32 [0.24, 0.42]	•
Total events	85		276				1 200 A
Heterogeneity: Tau* = 0.09; Cl	h#= 20.60	df=13	(P=0.08	0;1=3	7%		the state of the second
			STATISTICS.	22000			0.01 0.1 i tõ 100
Test for overall effect Z = 8.06	5 (P + 0.000	01)		28.507			Favours (experimental) Favours (control)

Figure 4: Meta-analysis of the total effectiveness rate of external application of Ruyi jinghuang powder versus conventional therapy based on the same intervention strategies. CI indicates confidence interval.

A: Chemotherapy-induced phlebitis

	ligner.	100	1 and	£.,		Note Factor	Test faile		
Rofe in Tabletone	Jun.	144	bets.	164	Real	BARANDER, BILD	Rister	0.05.0	
1.8144.300			10	18	1179	0.41.18.2.38		and the second s	
30444.381	10	- 61	- 34		17.96	1401.00.010			
No. Non-New York	- 14	- 36	1.0	- 18	104	2.00.2.496		June 1 and	
0.014.001	- 18	- 18	- 38	18	1075	1.02003.121			
ling M, and Tang S, 1974	- 18	- 18	- 18	18	113%	204230-046		and the second	
NAME	- 18	10	- 18	18	1105	18/03/05/06		Comparing Com	
No UT et al. (200	- 28	18	- 16	3	ΠØ.	CERTIN			
400.0		10		10	ine.	10000.000		•	
the prefix	111		12						
eeropenety test+333 C	estit,	8-11	+198	NB	÷		0.0	1 1 1	
and the second advect of a list of	P+100	R					1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Conception of the local division of the loca	

B: PICC-induced phlebitis

	Igen	666	1 July	£1.		list late	Tina Autor		
Rock on Subscript	line.	144	Just.	164	Real	84, April 19, 27, 27	Mill Randon, 875 Cl		
18184381	1.1	T	1	18	3175	OHLIGHT.	the second se		
UNITED BY A DESIGN AND A DESIGN A	100	- 48	1		17.96	1000.00			
hep is and herp HC2018.	- 14	10		18	1.12	2.010.21.455	and the second second		
0.0 ex 201		18	18	18	11.75	1.0210.171	1000		
King M, and Yang S, 1014	- 9		- 18	10	11.04	2042.06,146	(Transformer)		
544.44.00	- 18	- 38	- 18	14	110	1873.00.250			
3oU 4x,004	- 28	1	. 1	B	114	1,2,516,142			
immo.		10		10	ine,	10103-000	•		
Tala and the	110		10	1	1				
Helengenetic Taufin 232 C	estist.	i-ii	1.1383	hite	6				
her for some official division	8-120	N					10. 07 1 (1) 2 Heart Internetial Facult Institut		
							ranar and rank rank former		

Figure 5: Meta-analysis of the total effectiveness rate of external application of Ruyi jinghuang powder versus conventional therapy based on the same intervention strategies. CI indicates confidence interval.

C: Infusion phlebitis

	Lapson	ond i	- Deel	w .		Reak Ruths	Heat Autor		
Tolk a belana	- Desits	1114	Junt.	.Telal	Mode.	Mith Randoni, MYA CI	M H, Ramilan, WOLD		
Den Weiss Jill	- 74	1.16	174	. 10	4.0%	1.460.07,140	distribution of		
No. #853814	1.04	47	10	1.64	115	1.440.05.1.62	(Tradition)		
44 YM 40 41 (2005	- 32	12	-15	110	1.0%	2 19:2 46, 2102	the second se		
loaning trial and Los (2008)	18	31	18	10	4.9%				
Annual and Charlog M 2011		10	12	. 18	41%		the second second		
CT05, M H . 101	- 40	140	- 38	40	114				
(AB at al. 2018	27		- 14		1.65				
ALTE # 41.2013	- 194	- 68	40	1.60	1.04		+		
Aria, al-al. 2014	- 14	- 34	14		4.9%				
Au 10 3010	1.1	- 6	- 44	- 68	115		the second se		
fang fi ann Weng, Willmil		- 5	- 58	- ii	175		and and a second s		
Ru 1 20+1		11	- 97	- 6	115				
ian HL and Ru HYDETE	- 54	- 34	- 11	- 14	10				
ong mutimit	1.00	37	10	- 14	4.1%		and the second s		
No ORCOTT	#1	43	11	41	6.19				
UKOD W	1.00	- 10	- 14	- 40	115				
hargi,matai,2007	- 5	- 5	- 54	- 2	1.15				
bang init and (basi (0701-8	- 3	- 2	- 5	- 2	1.1%	THEAT			
card to and then in the s				1.5		Contrast.	1000		
1000 1001-13		100		10	16.01	121211-0.128	•		
1004 events	10		- 514						
Intercently Tev ² + U.S.L.C.	PORT.	8117	P+10	811.7	1.075		A A A 1		
Heldersgareetly TeuP + 0.01, 02 Teache nomali affect 2 × 3.02					- 119		Fill D French		

D: Indwelling needle-induced phlebitis


	Lapores	16	100	10		Red Bally	Real Ages
Bally or Salay sala	Date:	104	Loose,	144	Read.	Millionini, Well-	Hild, Rambins, Mills Cl.
(a) (5 and 2002 (7 301) Beng (5 301) Role (6 301) No.01 at at 2011 No.01 at at 2011			1000	日本の日本	1078 1188 1188 1188 1198	1.09(10),110	•
Tala (MTL) (b) Tala menti represente Tala (102) Tala to second effect (2 + 1	10 C 10 C 10 C	. 19 6. 81 18	. ()4 1/511	40 11.7	115	CHILIN USE	H D H H

Figure 6: Meta-analysis of the total effectiveness rate of external application of Ruyi jinghuang powder versus conventional therapy based on the same intervention strategies. CI indicates confidence interval.

	10	deal	÷.	1	184			Rathers		Sectoria .				
Set a Maria	84.		144	34	. 8	144	teres.	A Series Mill			Series, St.	- B		
tan / 44 (tr	104	11	- 18	- 64	115	. 8	10.05	4103-048, 1916						
10.00	10.7	33	. 4	22	28	14	10.5	441,402,008						
Sec.38	1.0	11.1	1	18	.83	1	11/6	40008-010						
B-0-44 (01)	1	11		1	14		1446	40101012-0100		-				
INCOMENDATION AND	10	10	18		18		103.	400016-000						
100.00.000.00000	10	101	18	111	16		105	10101-00		-	28			
he mechanism.	1	11	1	-	14	1	16	101111						
anin a			10			iii	ins.	ETTAR AND			•			
television fairs (617)	inte i	164	n i f	-18	11.5	18			100	- 10	-		-1	
factor and also () > 1.0	8-33	8				-			٦.,		a la			

Figure 7: Meta-analysis of the average healing time of external application of Ruyi jinghuang powder versus conventional therapy

Pain relief time



Three studies contained 200 patients reported pain relief time, the experimental group included 100 trials and the control group included 100 trials. The 3 trials yielded significant heterogeneity (χ^2 =11.48, *P*=0.003, *f*=83%), the

results of meta-analysis using the randomizedeffect model indicated significant difference on pain relief time of phlebitis (MD= -3.29, 95% CI =[-5.42, -1.16], P=0.002), as illustrated in Figure 8.

Figure 8: Meta-analysis of the average healing time of external application of Ruyi Jinghuang powder versus conventional therapy

Incidence time of phlebitis

Two RCTs consisting of 368 patients illustrated the results. The experimental group included 184 trials and control group included 184 trials. These 2 trials yielded significant heterogeneity (χ^2 = 17.44, *p* < 0.0001, *l*² = 94%), but result of metaanalysis indicated there was no statistical significance in incidence time of phlebitis (MD = -0.62, 95 % Cl = [-1.76, 0.52], *p* = 0. 29), as demonstrated in Figure 9.




Figure 9: Meta-analysis of the incidence time of phlebitis of external application of Ruyijinghuang Powder versus conventional therapy

Adverse events

Only one patient reported adverse event as rash reaction with topical application of Ruyi Jinhuang powder mixed with distilled water, manifested as local skin irritation, itching, neck visible red rash, after removing the topical drug immediately and intramuscular injection of diphenhydramine 20 mg was given at the same time, rash symptoms relieved within 30 min [26]. No other study has reported adverse events induced by Ruyi jinhuang powder. However, the effect of Ruyi jinhuang powder expression still need to further standardize and clear, usage of unknown "for external use" has become the underlying causes for the incidence of adverse reactions [27,28].

Sensitivity analysis

Using the leave-one-out approach, sensitivity analysis demonstrated the finding was reliable and independent, no significant change was noted in the direction of the combined estimates after the study removal, suggesting that the meta-analysis was robust and the data was accurate.

Publication bias assessment

In this review, although all of included literatures were the comparisons of the Chinese literature, the funnel plots of incidence of phlebitis, total effectiveness rate in treating phlebitis, average healing time, pain relief time, incidence time of phlebitis performed included 14 RCTs, 39 RCTs, 7 RCTs, 3 RCTs and 2 RCTs, respectively (Figure 8-10). The use of funnel plots of pain relief time and incidence time of phlebitis was limited because of the sample size. Regarding these studies of Ruyi Jinhuang powder for phlebitis, the publication bias was small because the spots were substantially symmetric, and none of the studies lies outside the limits of the 95%CI. However, caution is advised in interpreting the results of publication bias of average hospitalization time after operation because of a small subset of studies. Consequently, the publication bias probably occurs in this metaanalysis.




Figure 10: Funnel plot of the incidence rate of phlebitis with Ruyijinghuang Powder versus conventional therapy based on the same intervention strategies in preventing phlebitis




Figure 11: Funnel plot of the total effectiveness rate of phlebitis with external application of Ruyijinghuang Powder versus conventional therapy based on the same intervention strategies




Figure 12: Funnel plot of the average healing time of phlebitis with external application of Ruyi Jinghuang powder versus conventional therapy based on the same intervention strategies

DISCUSSION

Summary of evidence

This systematic review searched a wide variety of electronic databases for relevant articles. A total of 53 RCTs were identified, a detailed subgroup analysis based on different comparisons revealed the clinical outcome of phlebitis. Despite the fact that most of the trials had small sample sizes and poor methodological quality, analysis of the pooled data showed a consistently superior effect of Ruyi Jinhuang powder in terms of increasing the total effectiveness rate, which is in accordance with the prior two meta-analyses [8,9]. Whereas, reducing the incidence of phlebitis, which was not consistent with previous study [9], one important probable cause was the expanded sample size. Furthermore, our study showed that Ruyi jinhuang powder could even lead to a shorter postoperative recovery time bv decreasing average healing time and pain relief time of phlebitis compared to the control groups, which were not mentioned in the two prior studies. However, result of meta-analysis indicated there was no statistically significant difference in incidence time of phlebitis. Moreover, no patients dropped out of their trials due to adverse effects, suggesting that Ruyi Jinhuang powder was relatively safe for clinical use.

Strengths of this review

The prior two meta-analyses of Ruyi Jinhuang powder demonstrated significant benefits compared with 50% magnesium sulfate and no adverse drug reaction has been reported [8,9]. Sex trials were trials were included in one study, the obvious effective rate was statistically different [OR = 11.07, 95%CI 4.39-27.91, Z= 5.10, P<0.001] [8], whereas ten RCTs were included in another study, the total efficiencies of the two drugs had statistical significance [RR=12. 96, 95 % CI (5. 81, 28. 89), p < obviously effective rates 0.00001], were statistically different [RR = 9.11, 95 % CI (3.98, 20.88), p < 0.00001, but there was no statistical difference between Ruyi Jinhuang powder and magnesium sulfate in the incidence of phlebitis and grade I skin injury in the 72 h of treatment [RR = 7.76 and 0.13, 95 % CI: (0.94, 64.19) and (0.02, 1.07), p > 0.05 [9].

Limitations of this review

Even with these promising results, there are some limitations of the present study. First, although we were confident that our search strategy located all relevant studies, there remained a certain degree of uncertainty. Our study based on the findings of others about the heterogeneous quality of randomized trials from China. In our own experience in China, we have doubted that many methodological features attributed to randomized trials, were in fact conducted, while several explanations for this phenomenon existed, a likely explanation was the slow uptake of evidence-based medicine and clinical trials methodology in academic research centers. Second, the quality scores of the included RCTs were generally poor. Risk bias study showed that many of the studies are unclear with high risks in allocation concealment, blinding of participants and personnel, as well as outcome assessments. The unclear and high risk of bias in the included studies weakens the conclusion and well-designed randomized clinical trials are warranted to confirm the efficacy of Ruyi Jinhuang powder. While Cochrane's P2 and P2 tests revealed no statistical heterogeneity among these studies.

Possible rationale for use of Ruyi jinhuang powder for phlebitis

According to the TCM theory, first, the primary pathogenesis of phlebitis stagnated blood obstructing meridians and collaterals, resulting in such symptoms and signs as ischemia, thrombosis, ecchymosis and localized pain. Second, animal experiments carried out in recent years have demonstrated that phlegm-dampness firstly formed in these patients and then developed into stasis, resulting in combination of phlegm and stasis. Third, spasm and obstruction of the blood vessels will induce circulatory impairment of the affected limb, manifested by pallor, aversion to cold, distension pain, severe

pain and muscle twitch. Last, damp-heat of phlebitis is manifested by redness, edema and slightly infected gangrene. Therefore, treating basic principles is to invigorate blood circulation and remove blood stasis, resolving phlegm and dredging meridians and collaterals, warming Yang and relieving spasm and cleaning up toxic heat. In conclusion, external application of Ruyi Jinhuang powder using on treating and preventing phlebitis an important as complementary therapy is based on these definite principles [26-44].

This powder can shorten the time of licking, which shown that this powder has analoesic (P<0.05) [36.42]. effect Another clinical observation of golden powder combined with external application of antibiotics on epididymitis and orchitis shown that in the clinical efficacy significantly differed (P<0.05) and the scrotum in the treatment group in the signal measurement of blood levels, TCM syndrome, body temperature returned to nominal time, and the disappearance time of scrotal swelling and the disappearance time of clinical symptoms. The incidence of complications in these two groups was significantly lower than that in the control group (P<0.05) and yielded no adverse reactions [56]. What's more, Jinhuang powder-polyurethane dressing, a suitable material for temporary wound coverage of traditional Chinese orthopedics. was based on the famous prescription Ruyi Jinhuang powder. Polyurethane can absorb liquid higher than nearly 15-20 times of its own weightdue to excellent suction performance. Using immersion method to make the Jinhuang powder-polyurethane dressing can have high drug-loading capacity, which can be applied to the acute wound of Guinea pig and plays a role in mitigating inflammatory responses and eliminating necrotic tissues without irritation to the skin [48].

Implications for research

As an important complementary therapy, although a substantial amount of research has investigated the chemical constituents of Ruyi jinhuang powder. However, more trials with rigorous methods of design, measurement and evaluation (DME) following the Cochrane Handbook should be applied to enhance the representativeness of the sample. Clinical trial registries should be specifically encouraged to provide details of the protocols for treating phlebitis, placebo-controlled clinical trials are essential. Randomized controlled trials. for instance, should be strictly required in study design and reported based on the Consolidated Standards of Reporting Trials (CONSORT).

CONCLUSION

This systematic review demonstrates positive evidence for the effectiveness of Ruyi jinhuang powder in the management of phlebitis. Nevertheless, extreme heterogeneity in the analyses remains unexplained, and the number of high-quality studies was not large enough in this systematic review; thus, the outcome of the review is not conclusive. Therefore, more highquality RCTs, with low risk of bias and adequate sample sizes, are required to demonstrate its true effects.

DECLARATIONS

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

REFERENCES

- Barruel GR, Cert G, Polit DF, Murfield JE, Rickard CM. Infusion phlebitis assessment measures: a systematic review. J Eval Clin Pract 2014; 20: 191-202.
- Tagalakis V, Kahn SR, Libman M, Blostein M. The epidemiology of peripheral vein infusion thrombophlebitis: a critical review. Am J Med 2002; 113: 146-151.
- Tzolos E, Salawu A. Improving the frequency of visual infusion phlebitis (VIP) scoring on an oncology ward. BMJ Qual Improv Rep 2014; 3: u205455.w2364.
- Myrianthefs P, Karatzas S, Baltopoulos G. Complications, thrombophlebitis rates, and intravenous catheter replacement strategies. Infection 2005; 33: 96-97, 98-100.
- Lutzow-Holm C, De Angelis P, Clausen OP. Retinoic acid provokes a regeneration-like proliferative response in murine epidermis. A bivariate DNA/bromodeoxyuridine flow cytometric study. Arch Dermatol Res 1992; 284: 418-423.
- Malach T, Jerassy Z, Rudensky B, Schlesinger Y, Broide E, Olsha O, Yinnon AM, Raveh D. Prospective surveillance of phlebitis associated with peripheral intravenous catheters. Am J Infect Control 2006; 34: 308-312.
- Di Nisio M, Peinemann F, Porreca E, Rutjes AW. Treatment for superficial infusion thrombophlebitis of the upper extremity. Cochrane Database Syst Rev 2015; (11): CD011015.

- Qin SW, Lan QH, Xia YH. Meta-analysis of efficacy on satisfactory golden powder to treat patients with phlebitis. The Journal of Nursing Research 2010; 24: 85-87.
- Li GH, Jia YJ, Su S, Xia K. Evidence-Based Pharmacy Evaluation of Ruyi Jinhuang Powder for Treating Phlebitis. Chinese Pharmacology Journal 2012; 47: 1860-1862.
- 10. Ezzo J, Berman BM, Vickers AJ, Linde K. Complementary medicine and the Cochrane Collaboration. JAMA 1998; 280: 1628-1630.
- Zhang L, Li N. Effect observation of external application of Ruyi jinghuang Powder combined with winegar in prevention of phlebitis. E-journal of Translational Medicine 2016; 3: 15-17.
- Yang X, Ma JR, Yan XT, Cai YS, Ma WG. Curative effect observation of Ruyi Jinhuang powder combined with magnesium sulfate injection in prevention of fluorouracilinduced phlebitis of 30 patients. Hebei Journal of Traditional Chinese Medicine 2013; 35: 1184-1185.
- Jiang YJ. Clinic observation of Ruyi Jinhuang powder packed with honey to prevent chemotherapy phlebitis of 30 patients. Fujian Medical Journal 2010; 32: 168-170.
- Li J. Curative effect observation of Ruyi jinhuang powder combined with sodium β-seven in preventing of blistering chemotherapy drugs-induced phlebitis. Chinese Journal of Misdiagnostics 2012;12: 1080-1082.
- Cheng HJ, Qi ZP, Wang YL. Clinical observation and nursing of topical treatment of Ruyi golden powder in the treatment of 5-fu-induced phlebitis. Chinese Journal of Misdiagnosis 2012; 12:1309-1310.
- 16. Zhou MR. Topical treatment of Ruyi golden powder in the treatment of chemotherapy phlebitis of 24 patients. Herald of Medicine 2013; 32:75-76.
- 17. Sun HX, Li HX. Therapeutic effects observation of Ruyi Jinhuang powder paste used as external treatment of chemotherapeutic phlebitis. Chinese Journal of Modern Nursing 2015;21: 4039-4040.
- Yu ZP, Wu XQ, Liu JH. Observation in effect of wet compress with traditional Chinese medicine in treatment of chemotherapeutic phlebitis caused by indwelling needle. Chinese Journal of Practical Nursing 2010; 26: 40-43.
- You MN, Ding Y, Shang J. Comparison of treatment effect of hirudoid and ruyijinhuang powder for phlebitis caused by chemotherapy. Chinese Nursing Management 2010; 10: 62-63.
- 20. Wu H. Nursing experience in the treatment of chemotherapy-induced phlebitis. Journal of Traditional Chinese Medicine 2008; 14: 64- 64.
- Liu BR. Curative effect observation of topical treatment of Ruyi Jinhuang powder mixed with honey in the treatment of PICC-induced mechanical phlebitis. International Journal of Nursing 2011; 30:152-153.
- 22. Liang YF. A contrastive study of Ru-yi-jin-huang-san and 50% magnesium sulfate in treating of chemotherapeutic phlebitis. Chinese and Foreign Medical Research 2012; 10: 20-21.

Trop J Pharm Res, March 2019; 18(3):665

- 23. Meng QH. Clinic nursing observation of Ruyi golden powder mixed with dense tea water in treatment of chemotherapy-induced phlebitis nursing. Journal of Qiqihar University of Medicine 2011; 32: 2522-2523.
- 24. Kuang CX, Shen FL, Zhou XM. Therapeutic effect observation of the external application of Ruyi Jinhuang Powder in the treatment of chemotherapy non exosmosis phlebitis, China Practical Medicine 2013;8: 174-175.
- 25. Wang Y, Ge FJ, Jin YY, Mao L. Clinical nursing observation of hydropathic compress of Ruyi golden powder in prevention of phlebitis caused by chemotherapy drugs, Asia Pacific Traditional Medicine 2014;10: 116-118.
- He WG. External application of Ruyi golden powder in the prevention of phlebitis caused by chemotherapy drugs of 39 cases. China's Naturopathy 2012; 20: 15-16.
- Wei HA. Curative effect observation of external application of Ruyi jinhuang powder in preventing of phlebitis caused by chemotherapy drug. Chinese Journal of Coal Industry Medicine 2009; 12: 1896-1897.
- Liu LH, Yin XY, Wang AZ. Effect observation of external application of Ruyi Jinhuang powder in the treatment of PICC-induced mechanic phlebitis. Guangming Journal of Chinese Medicine 2015; 30: 2345-2346.
- 29. Li XM, Li YS. Effect observation of Ruyi Golden Powder in treatment of phlebitis. Guide of China Medicine 2013; 20: 278-279.
- 30. Gao YQ, Li L. Curative effect observation of Ruyi Jinhuang powder combined with infrared irradiation in prevention of PICC-induced mechanical phlebitis. Nursing and Rehabilitation Journal 2012;11: 369-310.
- Liu Y, Yang LY. Therapeutic effect observation of the external application of Ruyi Jinhuang Powder in the treatment of PICC-induced mechanical phlebitis. Journal of North China Coal Medical University 2009; 11: 671-673.
- Duan PP, Mei SJ, Zhang YY. The Prevention and Therapeutic Effect of Externally Applied Jinhuang Powder on PICC-induced Mechanic Phlebitis. Journal of Nursing (China) 2008; 15: 71-73.
- 33. Zhu LR, Li JZ, Wang XY. Observation on curative effects of Ruyi Jinhuang San mixed tea on phlebitis after PICC catheterization in elderly patients. Chinese Journal Modern Nurse 2008;14: 1463-1465.
- Li JH, Fan AF, Zhong CC. Curative effect observation of topical treatment of Ruyi Jinhuang powder in treatment of PICC-mechanical phlebitis. The Journal of Qiqihar Medical College 2007; 28: 1245-1246.
- Zhu AL, Chen CY, Wu J. Curative effect observation of topical treatment of Ruyi Jinhuang powder in treatment of PICC-mechanical phlebitis. Chinese Journal of Misdiagnostics 2009; 9: 2330-2331.
- Peng W, Wang HD. The efficacy of wet compress with Jinhuang San for phlebitis after chemotherapy. Chinese Journal of Medicinal Guide 2012; 14: 135-137.
- 37. Shi XY, Jia H, Fan AF, Gong HQ. Effect of Ru Yi Jin Huang powder on phlebitis during the intermittent period

of PICC treatment, Journal of Hainan Medical University 2011; 17: 312-314.

- Yao GM. Curative effect observation of Ruyi Jinhuang Powder mixed with white vinegar for the treatment of phlebitis. Medical Information 2015; 28: 269-270.
- Huang HM. Liu Y. Effects of treatment of phlebitis by using Ruyijinhuang Powder and honey. Nanfang Journal of Nursing 2004; 11: 44-46.
- 40. Yu H. Curative nursing observation of topical treatment of Ruyi jinhuang powder in treatment of drug induced phlebitis. Clinical Journal of Chinese Medicine 2016; 8: 124-125
- Wu X. Efficacy observation of Ruyi jinhuang powder mixed with Honey in treating of Kabiven injectioninduced phlebitis. World Latest Medicine Information 2015; 15:149-150.
- 42. Yan HL, Xu KY. Curative effect observation of topical treatment of Ruyi golden powder mixed with ethanol in the treatment of phlebitis. Today Nurse 2015; 11: 116-117.
- 43. Liu XL, Xi H, Wang HT. Therapeutic effect observation of the external application of Ruyi Jinhuang powder mixed with green tea in treating infusion phlebitis. Public Medical Forum Magazine 2014; 18: 4840-4842.
- 44. Zhang LH, Dong JY, Zhang JH, Fu L. Observation on the therapeutic effects of treating phlebitis by Ruyijinhuang powder mixed with dense tea. Acta Academiae Medicinae Cpapf 2007; 16: 133-135.
- 45. Liu XN, Zhang YN, Quan XN. Curative effect observation of topical treatment of Ruyi Jinhuang powder mixed with honey in the treatment of amiodarone-induced phlebitis, Shaanxi Journal of Traditional Chinese Medicine 2012; 33: 1638-1640.
- Zhang XH, Zhao XY. Curative effect observation of topical treatment of Ruyi golden powder in treatment of amiodarone-induced phlebitis. World Latest Medicine Information 2015; 15: 165-167.
- 47. Dai WD. Study on external application of Ruyi jinhuang powder mixed with dense tea water in the early intervention of amiodarone-induced phlebitis, The Chinese and foreign health abstract 2013; 42: 83-84
- 48. Huo LR, Chang XM. Clinic observation of TDP lamp irradiation combined with Ruyi Jinhuang powder in treating phlebitis caused by amiodarone. Journal of Huaihai Medicine 2013; 31: 267-268.
- 49. Chen ZF, Wu J, Qian HJ, Chen LH. Comparison of effective outcome of application of Rnyi golden powder and magnesium sulfate in the treatment of phlebitis caused by amiodarrone. Chinese Journal of Practice Nursing 2013; 33: 21-24
- 50. Fu XR. Therapeutic effect observation of the external application of Ruyi Jinhuang Powder in treating phlebitis caused by sodium β-seven. Clinical Journal of Chinese Medicine 2016; 8: 55-56.
- 51. Li FL, Liu Y, Chen LQ. Ruyi Jinhuang powder wet compress plus microwave physiotherapy treatment of fat emulsion induced phlebitis curative effect observation.

Trop J Pharm Res, March 2019; 18(3):666

Journal of Hunan University of Chinese Medicine 2013; 33: 36-37.

- 52. Yang WJ. Ruyi. Efficacy comparison of topical treatment of golden powder combined with magnesium sulfate in the treatment of mannitol-induced phlebitis. Journal of Psychological Doctors 2012; 10: 292-293.
- 53. Tang G, Meng JH. Curative effect observation of topical treatment of Ruyi jinhuang powder combined with glycerinum in the treatment of Gadopentetate dimeglumine injection-induced phlebitis. Guangming Journal of Chinese Medicine 2012; 27: 260-262.
- 54. He YH, Zhao HM, Han X. Clinic observation of topical treatment of Ruyi Jinhuang Powder mixed with vinegar for phlebitis caused by allitride injection. Today Nurse 2009; 2: 60-63.
- 55. Li RB, Wang S, Hu XN. Effect of dermlin dressing applying in elderly patients with superficial phlebitis. Chinese Journal of Nosocomiology 2010; 20: 795-797.
- 56. Mei R. Comparison of effectiveness between dermlin and the powder of Ruyij inhuang on superficial phlebites caused by long-term continuous intravenous injection treatment. Journal of Nanchang University (Medical Science) 2010; 50: 78-79.
- Zhang SZ, Wang Y. A study of prevention of the occurrence of superficial phlebitis with externally applied Ruyi Jinhuang powder. Medical Information 2013; 26: 28-29.
- 58. Zhou FF, Fan ZR, Xiao ZA. Clinical observation of topical treatment of Ruyi golden powder in prevention of venous indwelling needle-induced phlebitis caused by continuous drip 5-fu. Journal of Qilu Nursing 2012; 18: 28-29.

- 59. Yu XY, Tan HY, Du XY. Clinical observation of topical treatment of Ruyi golden powder in the treatment of indwelling needle-induced phlebitis. Chinese and Foreigh Medical Research 2010; 8: 57-59.
- Li XY. Clinical effects of Ruyi golden powder in patients with superficial venous indwelling needle and phlebitis. Nursing Journal of Chinese People's Liberation Army 2012; 29: 71-73.
- Xu JX, Hong QX, Jiang YS, Le YH, Hong Guo. Efficacy observation 50% alcohol harmonic ruyi jinhuang powder combined with lamp local irradiation for the treatment of indwelling needle-phlebitis. Medical Information 2011; 24: 3792-3793.
- 62. Song LL, Zhang QM, Shi JY. Curative effect observation of topical treatment of Ruyi Jinhuang powder mixed with Sesame oil in treatment of venous indwelling needleinduced phlebitis. Chinese Journal of Geriatric Care 2014; 12: 113-115.
- 63. Liu ZX, Zhou ZF. Curative effect observation of topical treatment of Ruyi jinhuang powder mixed with honey on phlebitis caused by intravenous indwelling needle. Guiding Journal of Traditional Chinese Medicine and Pharmacy 2012; 18: 126-127.
- 64. LA Gorski. Infusion Nursing Standards of Practice. Journal of Infusion Nursing the Official Publication of the infusion nurses society 2007; 30: 151.
- 65. Higgins JP, Altman DG, GotzscheP C, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d592.